Author:
Singh Ram B.,Chakravorty Saibal,Elmaraghi Osama,Nabavizadeh Fateme,Elkilany Galaleldin Nagib,Jain Meenakshi,Shukla Ashok K.,Agarwal Ajay,Yaduvanshi Amitabh,Mahajan Sanjay,Patel Vikas K.
Reference60 articles.
1. SGLT2 inhibitors and the heart. A view point;Halabi;World Heart J,2022
2. Sodium glucose transporters (SGLT2) inhibitors with reference to SGLT2-1 inhibitor;Singh;World Heart J,2022
3. Effect of chronotherapy with empagliflozin, among patients with type 2 diabetes mellitus. A non-randomized, single blind observation;Singh;World Heart J,2022
4. SGLT2 inhibitors reduce heart failure hospitalization and cardiovascular death: clarity and consistency;Wiviot;J Am Coll Cardiol,2023
5. Effects of empagliflozin on pro-inflammatory cytokines and other coronary risk factors in patients with type 2, diabetes mellitus. a single arm real world observation;Singh;Int J Clin Pharm Ther,2021